Evidence map›Paper›PMID 41159736›Full record

ArticleAntimicrobial agents and chemotherapy2025

Mutations in two-component signaling systems drive experimental evolution of tigecycline and colistin resistance in

J E Kent, M Elane, S Leyn, J Zlamal, N Wong, M Aizin, C Zampaloni, S Louvel, A Haldimann, M Vercruysse and 1 more

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

J E Kent *Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA.ORCID 0000-0002-4856-525X
M Elane *Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA.
S LeynSanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA.
J ZlamalRoche Pharma Research and Early Development, Infectious Diseases Therapeutic Area, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
N WongSanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA.
M AizinSanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA.
C ZampaloniRoche Pharma Research and Early Development, Infectious Diseases Therapeutic Area, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
S LouvelRoche Pharma Research and Early Development, Infectious Diseases Therapeutic Area, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
A HaldimannRoche Pharma Research and Early Development, Infectious Diseases Therapeutic Area, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
M VercruysseRoche Pharma Research and Early Development, Infectious Diseases Therapeutic Area, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.
A OstermanSanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA.ORCID 0000-0002-3810-9824

Funding

Comparative resistomics of Gram-negative bacterial pathogensR01AI167977 · NIAID · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ANDREI L OSTERMAN · 2022 to 2026
$3.7M
National Institute of Allergy and Infectious Diseases 5R01AI167977NIAID NIH HHS R01 AI167977
6 · The paper itself

Abstract

The treatment of infections by

Indexed as

Acinetobacter baumanniiAnti-Bacterial AgentsColistinTigecyclineBacterial ProteinsDrug Resistance, BacterialDrug Resistance, Multiple, BacterialMethyltransferasesMicrobial Sensitivity TestsMutationMutation, MissenseSignal TransductionAnti-Bacterial AgentsBacterial ProteinsColistinMethyltransferasesTigecyclineantibioticsESKAPE pathogensexperimental evolutionresistance

Identifiers

PMID41159736
PMCPMC12691633

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.